

**Harvard Medical School/Harvard School of Dental Medicine
Curriculum Vitae**

Name: Sophia Adamia

work email: sofia.adamia@iliauni.edu.ge

Work Email: Sophia_adamia@dfci.harvard.edu

Nationality: Canadian (Birthplace - Country of Georgia), US permanent resident (Green Card holder)

Education

11/2006	PhD in Oncology	Cross Cancer Institute/ Experimental Oncology	Faculty of Medicine and Dentistry, University of Alberta
---------	-----------------	--	--

Courses

01/2005	Bioinformatics	Intensive Bioinformatics Course	Bioinformatics Canada/ Canadian Genetics Diseases Network
06/2016	Bioethics	Intensive Bioethics Course	The Kennedy Institute of Ethics, Georgetown University

Postdoctoral Training

12/2006- 05/2008	Postdoctoral Research Fellow	Medical Oncology/ Division of Hematologic Neoplasia	Dana-Farber Cancer Institute and Harvard Medical School
---------------------	---------------------------------	--	---

06/2008- 10/2013	Postdoctoral Research Fellow	Medical Oncology/ Division of Hematologic Neoplasia/Leukemia group	Dana-Farber Cancer Institute and Harvard Medical School
---------------------	---------------------------------	--	---

Faculty Positions:

2013-2019	Instructor of Medicine	Medical Oncology/ Division of Hematologic Neoplasia	Dana-Farber Cancer Institute and Harvard Medical School
11/2019	Associated Professor	Institute of Medical and Public Health Research	Illia State University, Tbilisi, Georgia

Other Professional Positions

09/99-06/00	Teaching Assistant	Faculty of Biological Sciences, University of Alberta, Canada
09/03-09/06	PhD student/scientist	National Institute for Nanotechnology, Alberta, Canada
09/2019-present	Senior Scientist/group leader	Dana-Farber Cancer Institute

Honors and Prizes

2000	Teaching assistantship award	Faculty of Graduate studies and Research, University of Alberta, Canada.
2001	75th Anniversary award, Faculty of Medicine and Dentistry	Faculty of Graduate studies and Research, University of Alberta, Canada
2001	Medical Sciences Graduate student award	Faculty of Graduate studies and Research, University of Alberta, Canada
2001	Applications of Microsystems and Nanotechnology to life sciences award	National Research Council Canada (NINT-NRC-CNRC)
2002, 2004	Waldenstrom's macroglobulinemia Young Investigator Fellowship	Waldenstrom's macroglobulinemia Foundation (IWFM)
2001-2006	Multiple myeloma Studentship	Faculty of Graduate studies and Research, University of Alberta, Canada
2003-2004	Alberta Cancer Board graduate student award	Alberta Cancer board, Canada
2004-2005	Alberta Heritage Foundation for Medical Research studentship (AHFMR)	AHFMR, Canada
2004-2006	Nanotechnology to life sciences award	National Research Council Canada (NINT-NRC-CNRC)
2005	Dr. Herbert Meltzer award	Cross Cancer Institute, Alberta, Canada
2006	National Cancer Institute of Canada (NCIC) award	National Cancer Institute of Canada (NCIC)
2008	AACR-WICR Brigid G. Leventhal Scholar-in-training award	American Association for Cancer Research (AACR)
2010-2011	AACR-Amgen, Inc. Fellowships in Clinical/Translational Cancer Research	American Association for Cancer Research (AACR)
2012-2014	ASH Scholar Award (Clinical/Translational Research Fellow)	American Society of Hematology (ASH)

2016	The DFCI 2016 Ethics Award	Dana-Farber Cancer Institute- Intensive Bioethics Course- The Kennedy Institute of Ethics, Georgetown, Washington DC
2016	SPORE in Multiple Myeloma Development Research Award	NIH grant 4P50CA100707-14
2017	Excellence in Cancer Research	Rowena and Charles Simberg family award.
2018	Brian D Novis Senior Research Grant	International Myeloma Foundation (IMF)

Committee Service

Local

2012-2014	Newsletter/seminars committee-Member	Dana Farber Cancer Institute Postdoctoral and Graduate Student Association
2014-present	Joint Committee on the Status of Woman (JCSW)	Harvard Medical School
2016-present	Ethics Advisory Committee (EAC)	Dana-Farber Cancer Institute

National

2009-2016	Advocacy Committee Member	National Postdoctoral Association (NPA)
2012-2014	American Society of Hematology Trainee Council	American Society of Hematology
2013-2014	American Society of Hematology-working group leader	American Society of Hematology working group organizing trainee sessions for upcoming ASH annual meetings
2012	Scientific Session co-chair Oral Session: 602. Disordered Gene Expression in Hematological Malignancy, including Disordered Epigenetic Regulation	54th The American Society of Hematology (ASH) Annual Meeting, Atlanta
2012	Abstract review committee	54th The American Society of Hematology (ASH) Annual Meeting
2013	Session co-chair –trainee days: Translational Career Development	55th The American Society of Hematology (ASH) Annual Meeting, New Orleans
2013- 2014	American Society of Hematology special committee member	American Society of Hematology Task Force on New Revenue Opportunities

International

2000-2003	Animal care committee at Cross Cancer Institute	Cross Cancer Institute, Alberta Cancer Board, Canada
2001-2003	Graduate Student Association at the Faculty of Graduate studies	University of Alberta, Canada

2002-2003	President of Graduate Student Association, Department of Oncology	University of Alberta, Canada
2003-2004	Department of Oncology Committee member (Graduate student representative)	Cross Cancer Institute, Alberta Cancer Board, Canada
2004-2006	Faculty of Graduate Studies Evaluation committee member	University of Alberta, Canada
2018-2019	Advisory board international member	Institute of Medical Research, Ilia State University, Georgia
2020-	Curriculum committee member PhD program for MD at School of Medicine	Institute of Medical Research, Ilia State University, Georgia

Professional Societies

2000-2001	Canadian Society of Immunology (CSI)	Canada
2002-2003	American Society for Microbiology (ASM)	United States
2001-2006	American Society of Hematology (ASH)	Member in training
2007-present	American Association for Cancer Research	Associate Member #147556
2008-2015	American Association for Clinical Oncology (ASCO)	Member #82615
2008-present	American Society of Hematology	Active Member #1015226
2016-present	International Myeloma Society (IMS)	Active Member
2017-present	The RNA Society	Full (Author) Member # 84-1222776

Grant and other Review Activities

2012	The Harvard Catalyst Advanced Imaging Pilot Research Grants and Concept Development Awards Program	Harvard Medical School (Ad hoc reviewer)
2014-2015	Chief Scientist Office Grant- Scotland; The CSO's Experimental and Translational Medicine Research Committee	Chief Scientist Office Grant- Scotland (Ad hoc reviewer)
2012	Abstract review committee	54th The American Society of Hematology (ASH) Annual Meeting
2015-	The Italian Ministry of Health (MOH)- biomedical research	The Italian Ministry of Health (MOH)
2017, 2019	Ohio Cancer Research grants	Ohio Cancer Research foundation (Ad hoc reviewer)
2021-	GACR	The Czech Science Foundation (Ad hoc reviewer)

Editorial Activities

Ad hoc Reviewer

2013-	Cancer Epidemiology, Biomarkers & Prevention (CEBP)-AACR journals
2013-	Molecular Cancer Therapeutics (MCT)- AACR journals
2013-	Cancer Immunology, Immunotherapy
2014-	Blood (ASH)
2014-	Clinical Cancer Research (CCR)- AACR journals

2016- Molecular Cancer Research America Association for Cancer Research (AACR) journals
 2016- BMC Cancer
 2017- The New England Journal of Medicine (NEJM)
 2017- Cancer Research (AACR Journals)
 2017- Blood Advances (ASH)
 2018- The Journal of Pathology

Consulting Activities

2015 Agios Pharmaceuticals Short-term consulting (Subjects- (1) Splicing factor mutations and mis-spliced RNA in AML and other hematological malignances; (2) Identification novel targets based on aberrant RNA splicing.)

Report of Funded and Unfunded Projects

Funding Information

Past

2009-2011 Genome-wide alternative splicing in AML -novel targets for antibody therapy
 AACR Research Fellowships in Clinical and Translational Cancer Research
 Role: PI
 The major goal of this international award was to identify novel therapeutic targets for patients with acute myeloid leukemia.

2012-2014 Investigating the cause of aberrant splicing in patients with acute myeloid leukemia
 The American Society of Hematology Scholar Award
 Role: PI
 The major goal of this project was to investigate the cause of increased aberrant splicing in patients with acute myeloid leukemia and define its clinical significance.

2013-2016 Aberrant splicing in AML: novel molecular markers and therapeutic targets
 The Leukemia and Lymphoma Society Translational Research Program
 Role: Key investigator – grant to PI James Griffin
 The major goal of this project is to develop approaches and strategies for novel therapeutics for patents with AML based on targets found through genome-wide alternative splicing screening of patients.
 This grant is based entirely on my work; I conceived the idea and wrote the grant.

2013-2016 Splice Variants as Targets for Therapeutic Antibodies for AML
 Research collaborations with Janssen Pharmaceutical (Johnson & Johnson)
 Role: Co-PI (Collaboration to Griffin)
 The goal of this project is to develop therapeutic antibodies based on novel splice variants identified through genome-wide splicing studies in patients with AML.

2016-2017 Discovery of novel therapeutic targets based on aberrant gene splicing in multiple myeloma (MM)
 NIH funded grant 4P50CA100707-14
 Role: PI
 The goal of this project is to develop therapeutic antibodies based on novel splice variants identified through genome-wide splicing studies in patients with Myeloma

- 2017-2019 Testing effects of the ERK1/2 Inhibitor – LY3214996 in myeloid malignancies AML and MDS
Lilly/Oncology collaboration (PI James D. Griffin)
Role: co-investigator
Pre-clinical studies; testing Erk1/2 inhibitors in combination with a standard treatment regimen. Initiated collaboration based on my proposal. Based on this pre-clinical study Phase 1 Study of LY3214996 in AML patients is initiated by Dr. Stone in collaboration with Eli Lilly.
- 2018 Functional role of core splicing factor deregulation in MM pathogenesis
2018 Brian D Novis Senior Research Grant-Award, International Myeloma Foundation
Role: PI
Goal of this study is identification causes and consequences of aberrant splicing in myeloma
- 2018-2020 Testing effects of the ERK1/2 and CDK4/CDK6 (Abemaciclib/Verzenio™) in combination in relapse refractory myeloma model systems.
Lilly/Oncology collaboration (PI: Kenneth C. Anderson)
Role: co-investigator.
Testing Erk1/2 and CDK4-6 inhibitors in combination with a standard treatment regimen for relapse refractory myeloma.

Current

- 2020-2023 Shota Rustaveli Science Foundation
Discovery and understanding role of epigenetic alterations in patients with hematological malignancies residing in Country of Georgia a region affected by Chernobyl explosion. Long-term goal of this project interest includes, understanding the broad effects of low-dose radiation on transcriptome changes through epigenetic mechanisms, including its effects on RNA splicing and its regulation in hematological malignancies
Role: PI (Adamia)
Co-PI: Maia Zarnadze
Key Personnel – Irina Datikashvili-David

Report of Local Teaching and Training

Teaching of Students in Courses

Harvard Medical School

- | | | |
|------|---|---|
| 2013 | Hallmarks of cancer
3 rd and 4 th year PhD and MD/PhD students | Harvard Medical School, Department Cell
Biology, Cancer Biology course, NRB350 |
|------|---|---|

Laboratory and Other Research Supervisory and Training Responsibilities

- | | | |
|--------------|--|--|
| 2007-present | Training of MD and MD/PhD postdoctoral fellows, DFCI, Boston, MA | Mentoring in research laboratory, aiding in developing a research project and writing fellowships. |
|--------------|--|--|

Formally Supervised Trainees

Canada

- 2003 -2005 Undergraduate student Viet Hoang, Department of Engineering, University of Alberta, Canada
Graduate program in Biomedical engineering
- 2004-2005 Undergraduate student Carrie McQuarrie, Dept. Sciences, University of Alberta, Canada
- 2005 1st year medical student Jennifer J. Hodges, University of Calgary Medical School/Cross Cancer Institute, Canada

USA

Fellows/Resident

- 2014-2015 Postdoctoral Research Fellow: Patricia Toniolo, PhD,
- 2014-2015 Resident: Ibiayi Dagogo-Jack, MD
- 2015- 2017 Resident: Natalie Vokes, MD
- 2017- 2018 Postdoctoral Research Fellow: Maia Meparishvili, PhD
- 2019 Visiting Research Fellow: Lisa Muller, PhD candidate, Düsseldorf Germany
- 2019-2020 Catherine Nicholas, Northeastern University, co-op student

PhD programs

- 2019- Anzor Chavchavadze, PhD candidate; PhD program in Biochemistry and Molecular Biotechnology, Country of Georgia
- 2020 Alexandre Kajrishvili, MD; PhD program in Medicine, Country of Georgia

Undergraduate/high school students

- 2007-2009 Hannah Mogul-Adlin - Boston Latin high school student
Massachusetts State Science and Engineering Fair- winner city wide and state wide
- 2013 Kaya Boss - Boston Latin high school student
Fredrick Joe-The John D. O'Bryant School of Mathematics and Science, Boston Technical High School
- 2014 Heven Volder- The John D. O'Bryant School of Mathematics and Science, Boston Technical High School
- 2015 Lorena Escolero, the Fenway High School senior student internship program student
- 2015 Akaki Tsivadze - Worcester Polytechnic Institute (WPI), Electrical and Computer Engineering, 2nd year.
Yang Cheng - University of Massachusetts Boston, Department of Biology
- 2017 Abigail Schwartz- Crest School, Fort Lauderdale, Florida
- 2017- 2018 Andrew P McGuire, Commonwealth School, Boston
- 2019-2020 Catherine Nicholas, Northeastern University, co-op student
- 2020- Morgan O'Keefe, Boston University
- present

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Regional

- 2013 Guest lecturer BIOL113 General Biology course: Lecture 1 Biotechnology, Lecture 2 DNA profiling and genomics
Guest lecturer at Simmons College, Boston

International

- 2010 MicroRNA profiling in multiple myeloma: clinical relevance and avenues for novel therapeutics
Magna Graecia University, Medical Oncology and “Tommaso Campanella” Cancer Center Catanzaro, Catanzaro, Italy
- 2017, September Alterations in RNA processing identifies novel disease biomarkers and drug targets for hematological malignancies.
Guest lecturer at the University of Alberta , Faculty of Medicine and Dentistry, Hematology Division

Abstract Oral Presentations

Regional

Canada

- 2002 Effects of extracellular matrix molecules on pathophysiology of Multiple myeloma
Immunology Network (ImmuNet) Retreat, Canada
- 2002-2006 Annual seminar series based on ongoing projects
Department of Experimental Oncology seminar series, Cross Cancer Institute
Canada
- 2003 Spread of Multiple Myeloma
Keynote speaker Young Scientists Conference, Canada
- 2002- 2006 Annual seminar based on ongoing projects
Division of Medical Oncology, Cross Cancer Institute, Alberta, Canada

USA

- 2007- present Annual seminar based on ongoing projects
Division of Hematologic Neoplasia seminar series, Medical Oncology, Dana-Farber Cancer Institute, Boston
- 2014-2017 RNA Splicing group seminar series, Boston Children’s Hospital
organized by Benjamin L. Ebert
- 2015- present Annual seminar based on ongoing projects, Beth Israel Deaconess Medical Center
Organized by Daniel G Tenen
- 2019 Department of Molecular, Cellular and Biomedical Sciences seminar series, University of New Hampshire.
Invited speaker
- 2019 HMS Initiative for RNA Medicine seminar series
Invited speaker

International

Abstract Oral Presentations

2002 Invited speaker	Overexpression and novel splice variants of hyaluronan synthases in Waldenstrom's macroglobulinemia 2 nd International Waldenstrom's macroglobulinemia workshop, Athens, Greece
2004 Invited speaker	Aberrant HAS1 gene splicing and genetic predisposition in Waldenstrom's macroglobulinemia 3 rd International Waldenstrom's macroglobulinemia workshop, Paris, France
2007 Invited speaker	Aberrant post-translational regulation of TNF family members and their adaptor molecules in pathways essential to B-cell growth and survival in Waldenstrom's macroglobulinemia Novel splice variants of SIVA in Waldenstrom's Macroglobulinemia Joint 11th International Myeloma and 4 th Waldenstrom's macroglobulinemia workshops, Kos, Greece
2008 Invited speaker	High-throughput microRNA profiling: Identification of miRNAs with a potential pathogenic role in Waldenstrom's macroglobulinemia 5 th International Waldenstrom's macroglobulinemia workshop, Stockholm Sweden
2008	miRNA Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy 50 th American Society of Hematology annual meeting, San Francisco, CA; Blood. 2008;112; Abstract 98
2009 Invited speaker at Plenary session	miRNA profiling identified distinct clinically relevant sub-groups in multiple myeloma 12 th Multiple Myeloma workshop, Washington DC
2009	Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma <i>in vitro</i> and <i>in vivo</i> 51 th American Society of Hematology annual meeting, New Orleans, LA; Blood. 2009;114; Abstract 833
2010	Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML) 52 th American Society of Hematology annual meeting, Orlando, FL; Blood. 2010;116; Abstract 177
2011	Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Identifies Potential Novel Targets 53 rd American Society of Hematology annual meeting, San Diego, California; Blood. 2011;118; Abstract 761
2012	Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Is Associated with Altered Expression of Splicing Factors 54 th American Society of Hematology annual meeting, Atlanta, Georgia; Blood 2012; 120; Abstract 652
2018 Invited speaker	Aberrant splicing in patients with myeloma is associated with modulated expression of PTBPs. 2 nd international conference -RNA splicing, Portugal.
2021 Invited speaker	Alternative RNA processing prospective RNA toolkit in myeloma cell therapy. XVI. Multiple myeloma & IV. Cell therapy workshop, Ostrava, Czech.

Report of Technological and Other Scientific Innovations

Cancer Monitoring and therapeutics. “HAS1 splice variants as diagnostic and monitoring tool” US Patent 2005003368. Class: Intl 435006000 (USPTO), C12Q001/68, 2004; published 2006

Method for Cancer Detection and Monitoring PCT/CA2006/000508. Publication date WO/2006/105650. Int. Class: C12Q 1/68 (2006.01), C12Q 1/04 (2006.01), G01N 33/574 (2006.01), published 2009

These innovations are based on my doctoral research findings

Report of Education of Patients and Service to the Community

Activities

- 2006 WM Symposium & Benefactor Dedication, DFCI, Boston, MA/invited speaker
- 2009 siRNA and microRNA. Bio Techniques Vol. 46, No 4, interviewed by Lederman L, Ph.D
- 2012 Brigham and Women’s Hospital (BWH) Kessler Library -“Twelve Weeks: An Artist’s Story of Cancer, Healing and Hope”-by Karen Lee Sobol- Organizing book promotional event.
- 2013 The Boston City Council’s Committee on Labor, Youth Affairs and Health; Docket #0451- ordered for a hearing regarding the resources and services available to individuals with sickle cell disease/ witness at a public hearing, Boston City Hall.
- 2016 May The Office of the state of Georgia for Diaspora Issues.
Diaspora Professional Forum “Share your experience to Homeland” –speaker.
- 2017 Special Guest participant -Racing with Randi- The Multiple Myeloma Research Foundation, FL
- 2020 Virtual MMRF 5k walk/run - “Fear Less”- International Team SA- Boston-Tbilisi
The Multiple Myeloma Research Foundation, FL
- 2021 Brushes with Cancer, Northeast program -organized by Twist Out Cancer
Art piece “Infinite Charge” by Michael Rosen & Sophia Adamia

Recognition

- 2008 and 2010 In recognition of the contribution to Boston Latin School’s Science mentor program The Boston Latin School, Boston, MA
- 2013 and 2014 In recognition of the contribution to mentoring minority students; program run through DFCI workforce development office Dr. Edward Benz Jr, President of Dana-Farber Cancer Institute
- 2017 The Georgian Diaspora Awards 2017 for the scientific achievements The ICMPD (European International Centre for Migration Policy Development) and the Ministry of Foreign Affairs of Georgia.
- 2018 Appreciation Award- 6th Annual Miracle for Myeloma 5K Race/Walk, International Myeloma Foundation, NJ

Report of Scholarship

Peer reviewed publications in print or other media:

H index = 26 Total of 2491 citations, over 100 citations per years since 2008

i10 index = 44

C. Complete List of Published Work in MyNCBI:

<https://www.ncbi.nlm.nih.gov/myncbi/sophia.adamia.1/bibliography/public/>

Research investigations

1. Goss GG, **Adamia S**, Galvez F. Peanut lectin binds to a subpopulation of mitochondria-rich cells in the rainbow trout gill epithelium. *Am J Physiol Regul Integr Comp Physiol*. 2001;281:R1718-5. ISSN 0363-6119.
2. **Adamia S**, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulinemia. *Semin Oncol*. 2003;30:165-8. ISSN 0093-7754.
3. Cen EG, Dalton C, Li Y, **Adamia S**, Pilarski LM, Kaler KV. A combined dielectrophoresis, traveling wave dielectrophoresis and electrorotation microchip for the manipulation and characterization of human malignant cells. *J Microbiol Methods*. 2004;58:387-1. ISSN 0167-7012.
4. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, **Adamia S**, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Jr., Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. *Blood*. 2004;104:1151-8. ISSN 0006-4971.
5. **Adamia S**, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. *Blood*. 2005;105:4836-44. ISSN 0006-4971.
6. Pilarski LM, Lauzon J, Strachan E, **Adamia S**, Atrazhev A, Belch AR, Backhouse CJ. Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma. *J Immunol Methods*. 2005;305:94-105. ISSN 0022-1759.
7. **Adamia S**, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. *Curr Drug Targets Cardiovasc Haematol Disord*. 2005;5:3-14. ISSN 1568-0061.
8. **Adamia S**, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM. Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. *Clin Lymphoma*. 2005;5:253-6. ISSN 1526-9655.
9. Pilarski PM, **Adamia S**, Backhouse CJ. An adaptable microvalving system for on-chip polymerase chain reactions. *J Immunol Methods*. 2005;305:48-58. ISSN 0022-1759.
10. Prakash AR, **Adamia S**, Sieben V, Pilarski PM, Pilarski LM, Backhouse CJ. Small volume PCR in PDMS biochips with integrated fluid control and vapor barrier. *Sens Actuators B: Chem*. 2006;113(1):398-409. ISSN: 0925-4005.
11. Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, **Adamia S**, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. *Exp Hematol*. 2007;35:1366-75. ISSN 0301-472X.

12. VanDijken J, Kaigala GV, Lauzon J, Atrazhev A, **Adamia S**, Taylor BJ, Reiman T, Belch AR, Backhouse CJ, Pilarski LM. Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts. *J Mol Diagn.* 2007;9:358-367. ISSN 1525-1578.
13. **Adamia S**, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. *Blood.* 2008;112:5111-5121. ISSN 1528-0020.
14. Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, **Adamia S**, Stone R, Galinsky I, Kung AL, Griffin JD. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. *Mol Cancer Ther.* 2008;7:1121-29. ISSN 1535-7163.
15. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, **Adamia S**, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. *Br J Haematol.* 2009;145:59-63. ISSN 1365-2141.
16. **Adamia S**, Pilarski PM, Belch AR, Pilarski LM. Genetic abnormalities in Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma.* 2009;9:30-2. ISSN 1557-9190.
17. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, **Adamia S**, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. *J Clin Oncol.* 2009;27:250-5. ISSN 1527-7755.
18. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, **Adamia S**, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. *Blood.* 2009;113:626-634. ISSN 1528-0020.
19. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, **Adamia S**, Kung AL, Gray NS, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. *Mol Cancer Ther.* 2010;9:2468-77. ISSN 1538-8514.
20. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, **Adamia S**, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. *Blood.* 2010;115:4206-16. ISSN 1528-0020.
21. Weisberg E, Deng X, Choi HG, Barrett R, **Adamia S**, Ray A, Moreno D, Kung AL, Gray N, Griffin JD. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. *Leukemia.* 2010;24:1375-78. ISSN 1476-5551.
22. Weisberg E, Ray A, Nelson E, **Adamia S**, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. *PLoS One.* 2011;6:e25351. ISSN 1932-6203.
23. Jakubikova J, **Adamia S**, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujovala D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. *Blood.* 2011;117:4409-19. ISSN 1528-0020.

24. Amin SB, Shah PK, Yan A, **Adamia S**, Minvielle S, Avet-Loiseau H, Munshi NC, Li C. The dChIP survival analysis module for microarray data. *BMC Bioinformatics*. 2011;12:72. ISSN 1471-2105.
25. **Adamia S**, Pilarski PM, Belch AR, Pilarski LM. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets. *Curr Cancer Drug Targets*. 2013;13:347-61. ISSN 1873-5576.
26. **Adamia S**, Pilarski PM, Bar-Natan M, Stone RM and Griffin JD. Alternative Splicing in Chronic myeloid Leukemia (CML): a novel therapeutic target? *Current cancer drug targets*, 2013 Jul 30 [Epub ahead of print]. ISSN 1873-5576.
27. **Adamia S**, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD. A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. *Clin Cancer Res*. 2014 Feb 11. [Epub ahead of print] PMID: 24284058.
28. **Adamia S**, Bar-Natan M*, Haibe-Kains B*, Pilarski PM*, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone RM and Griffin JD. NOTCH2 and FLT3 gene mis-splicing are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. *Blood*, 2014 Feb 26. PMID:24574459.
29. Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, **Adamia S**, Belch AR, Pilarski LM. Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not breast cancer. *PLoS One*. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691.
30. Cagnetta A, **Adamia S**, Acharya C, Patrone F, Miglino M, Nencioni A, Gobbi M, Cea M. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. *Leuk Res*. 2014 Mar 18. PMID: 24726781.
31. **Adamia S**, Kriangkum J, Belch AR, and Pilarski LM. Aberrant post-transcriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression. *Adv Cancer Res*. 2014;123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. PMID:25081526.
32. Cea M, Cagnetta A, **Adamia S**, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. *Blood*. 2015 Dec 16. pii: blood-2015-06-649970. [Epub ahead of print] PubMed PMID: 26675349.
33. Cagnetta A, Caffa I, Acharya C, Soncini D, Acharya P, **Adamia S**, Pierri I, Bergamaschi M, Garuti A, Fraternali G, Mastracci L, Provenzani A, Zucal C, Damonte G, Salis A, Montecucco F, Patrone F, Ballestrero A, Bruzzone S, Gobbi M, Nencioni A, Cea M. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. *Clin Cancer Res*. 2015 Sep 1;21(17):3934-45. doi: 10.1158/1078-0432.CCR-14-3023. Epub 2015 May 11. PubMed PMID: 25964294.
34. Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, **Adamia S**, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. *Leukemia*. 2015 Jul 23. doi: 10.1038/leu.2015.194. [Epub ahead of print] PubMed PMID: 26202935.

35. Cea M, Cagnetta A, **Adamia S**, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. *Blood*. 2015 Dec 16. pii: blood-2015-06-649970. PMID: 26675349.
36. Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, **Adamia S**, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. *Leukemia*. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13. PMID:26165234.
37. Fulciniti M, Amodio N, Bandi RL, Cagnetta A, Samur MK, Acharya C, Prabhala R, D'Aquila P, Bellizzi D, Passarino G, **Adamia S**, Neri A, Hunter ZR, Treon SP, Anderson KC, Tassone P, Munshi NC. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. *Blood Cancer J*. 2016 Jan 15;6:e380. doi: 10.1038/bcj.2015.106. PubMed PMID: 26771806; PubMed Central PMCID: PMC4742623.
38. Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, **Adamia S**, Stone RM, Galinsky IA, Brown JR, Griffin JD, Zhang S, Loh T, Zhang X, Wang W, Weisberg EL, Liu J, Liu Q. Characterization of selective and potent PI3K δ inhibitor (PI3KDIN- 015) for B-Cell malignancies. *Oncotarget*. 2016 Apr 12. doi: 10.18632/oncotarget. 8702. [Epub ahead of print] PubMed PMID: 27081697.
39. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, **Adamia S**, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, and Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. *Nat Chem Biol*. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2. PubMed PMID: 28967922.
40. Brunner AM, Neuberg D, Wander SA, Sadrzadeh H, Ballen K, Amrein P, Attar E, Hobbs G, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, **Adamia S**, Borger DR, Iafrate A, Graubert TA, Stone RM, and Fathi AT. Isocitrate Dehydrogenase 1 and 2 Mutations, 2-Hydroxyglutarate Levels, and Response to Standard Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia. *Cancer*. 2018 Nov 13. doi: 10.1002/cncr.31729. PMID:30422308.
41. Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, **Adamia S**, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. *Br J Haematol*. 2019;187(4):488-501.
42. **Adamia S**, Abiatari I, ^{Amin} SB, Fulciniti M, Minvielle S, Li C, Philippe Moreau P, ^{Avet}-Loiseau H, Munshi NC, and Anderson CA. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. *Leukemia*. 2020;34(1):167-179. doi: 10.1038/s41375-019-0498-5. PMID: 31182781
43. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Toure AA, Buhrlage S, Liu X, Wang J, Gray N, Stone R, **Adamia S**, Winer E, Sattler M, Griffin JD. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. *J Cell Mol Med*. 2020;24(3):2145-2156.

44. Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, **Adamia S**, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. *Br J Cancer*. 2020;122(8):1175-1184.
 45. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, **Adamia S**, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. *J Cell Mol Med*. 2020;24(5):2968-2980.
 46. Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, **Adamia S**, Griffin JD. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. *Leukemia*. 2020;34(2):625-629.
 47. Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, **Adamia S**, Ando K, Hideshima T, Anderson KC. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. *Blood*. 2020;136(20):2334-2345.
 48. Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, **Adamia S**, Zhu H, Kuang Y, Mogili A, Louissaint A, Jr., Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. *Cancer Cell*. 2020;38(6):872-890 e876.
- Chapters, and Proceedings of meetings
 1. Dalton C, **Adamia S**, Pilarski LM, and Kaler KVIS. Investigation of human malignant cells by electrorotation. In proceeding of: Electrical Insulation and Dielectric Phenomena, 2004. CEIDP '04. 2004 ISBN: 0-7803-8584-8585.
 2. Pilarski LM, **Adamia S**, Dalton C, Pilarski PM, Prakash AR, Kaler KVIS, and Backhouse CJ. Microfluidics Devices For Genetic Analysis Of Cancer. In proceeding of: 34th Annual Scientific Meeting of the Australasian Society for Immunology. 12/2004.
 3. Pilarski LM, **Adamia S**, Maxwell CA, Pilarski PM, Reiman T, Belch AR. Editors: Balazs EA and Hascall VC. "Hyaluronan Synthases and RHAMM as Synergistic Mediators of Malignancy in B Lineage Cancers." in "Hyaluronan: Structure, Metabolism, Biological Activities, Therapeutic Applications", Chapter 4, pages 329-338, Editors: E.A. Balazs and V.C. Hascall, Matrix Biology Institute, Edgewater, New Jersey, USA, 2005.
 4. Backhouse CJ, Footz T, **Adamia S**, Pilarski LM. Editors: W Badawy and W Moussa. Microfluidics Chips for Molecular Analysis of Human Cancer. Proceedings of the International Conference on MEMS, nano and Smart Systems. pp 377-382. The Printing House, SA, 2003.
 5. Pilarski LM, **Adamia S**, Pilarski PM, Prakash R, Lauzon J, Backhouse CJ. Editors: Badawy, W. and Moussa, W. Improved Diagnosis and Monitoring of Cancer Using Portable Microfluidics Platforms. Proceedings of the International Conference on MEMS, Nano and Smart Systems, 2004. pp 340-345.
 6. Linda M. Pilarski , Jitra Kriangkum, **Sophia Adamia**, Helga M. Ogmundsdottir, Andrew R. Belch. Waldenstrom's Macroglobulinemia Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis. Book Chapter, "Waldenstrom's Macroglobulinemia", Springer publishing 07. October 2017, pp35-48. **ISBN-13: 978-3319225838**

Thesis

Adamia S. The Role of Hyaluronan Synthase in Multiple Myeloma and Waldenstrom's Macroglobulinemia. A thesis for the degree of Doctor of Philosophy in Oncology. University of Alberta, Faculty of Medicine and Dentistry, Department of Oncology, and CCI, ACB, AB, Canada

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

(Selected from >100 peer-reviewed abstracts since year 2000)

1. **Adamia S**, Chyra Z, O'Keefe M, Bhatt S, Wen K, Nicholas C, Fell GG¹, Yu-Tzu Tai, Abiatari I, Letai A, Dorfman DM, Hideshima T, and Anderson KC. Identification of novel targets based on splicing alterations for undruggable RAS/CDK signaling cascade in multiple myeloma. *Blood*, 2021
2. **Adamia S**, Bhatt S, Tai Y-T, Wen K, Nicholas CA, Pioso MS, Abiatari I, Letai AG, Anderson K. Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM). *Blood*. 2020;136:22-23.
3. Chyra Z, Samur MK, Aktas-Samur A, Xu Y, Morelli E, **Adamia S**, Park WD, Charles L, Shammas MA, Hajek R. Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma. *Blood*. 2020;136:49
4. **Adamia S**, Ogiya D, Abiatari I, Verselis SJ, Chu MP, Dorfman DM, Pilarski LM, Hideshima T, Anderson KC. Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches. *Blood*, 2019.
5. Ogiya D, Müller L, Verselis SJ, Schaal H, Abiatari I, Stenstrom AM, Nicholas CA, Daley JF, Chu MP, Dorfman DM., Hideshima T, Anderson KC and **Adamia S**. Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy. *Blood*, 2019.
6. Ogiya D, Müller L, Verselis SJ, Hideshima T, Chu M, Schaal H, Dorfman DM, Pilarski LM, Anderson KC, **Adamia S**. Aberrant RHAMM (receptor for hyaluronan-mediated motility) splicing in MM is associated with upregulation of PTBP1/2 (polypyrimidine tract binding protein 1/2): therapeutic implications. *Clinical Lymphoma, Myeloma and Leukemia*. 2019;19(10):e123-e124.
7. Lisa Müller, Frank Hillebrand, Ivane Abiatari, Heiner Schaal, Kenneth C Anderson and **Sophia Adamia**. Mutations in splicing regulatory elements in RHAMM gene may contribute to an increased RHAMM-exon4/RHAMM-FL splice variant ratio in multiple myeloma (MM). 2019 RNA Therapeutics conference: From Mechanism to Therapy.
8. **Sophia Adamia**, Sigita J Verselis, Teru Hideshima, Michael P. Chu, Shruti Bhatt, David P. Steensma, Daniel J Deangelo, Richard M. Stone, Daniel G. Tenen, Linda M. Pilarski, James D. Griffin and Kenneth C. Anderson. Cell type-specific deregulation of Polypyrimidine Tract-Binding Proteins (PTBPs) drive aberrant splicing in multiple myeloma (MM) and acute myeloid leukemia (AML). *Blood* 2018 132:3895; doi: <https://doi.org/10.1182/blood-2018-99-118501>.
9. **Sophia Adamia**, Teru Hideshima, Sigita J Verselis, Zachary Hunter, Andrew P. McGuire, Michael Chu, Andrew Belch, David M Dorfman, Linda M Pilarski, Steven P Treon, and Kenneth C Anderson. Deregulated expression of PTBPs is associated with altered splicing in Myeloma (MM) and Waldenstrom's macroglobulinemia (WM). IWWM 10th International Workshop, NYC 2018.
10. **Sophia Adamia**, Teru Hideshima and Kenneth C Anderson. Identification Cause of Aberrant Splicing and Novel Drug Targets in Patients with Multiple Myeloma. *Blood* 2017 130:4340.
11. Shruti Bhatt, Vineeth Kumar Murali, Holly Zhu, **Sophia Adamia**, Amanda L Christie, David M Weinstock, Jackie S Garcia, Anthony Letai. Functional approach to precision medicine identifies targeted therapies for acute myeloid leukemia. *Blood* 2017 130:853.

12. **Sophia Adamia**, Mehmet Samur, Nikhil C Munshi, and Kenneth C Anderson. Identification causes and consequences of aberrant splicing in patients with multiple myeloma. Cold Spring Harbor Laboratory conferences, Eukariotic mRNA processing, Long Island, NY, 2017.
13. **Adamia S.** Nemeth J, Bhatt S, Walker SR, Voeks NI, Lento W, Attar RM, Galinsky I, Frank DA, Wadleigh M, Letai A, Steensma DP, Weinstock DM, DeAngelo DJ, Dorfman DM, Stone RM, and Griffin JD. FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). Blood. 2016; Abstract 1045.
14. Natalie I. Vokes, Patrick M. Pilarski, Cristian Bach, James D. Griffin, **Sophia Adamia**. Small non-coding RNAs as potential therapeutic agents for acute myeloid leukemia (AML). Cold Spring Harbor Laboratory conferences, Eukariotic mRNA processing, Long Island, NY, 2015.
15. Toniolo PA, Pilarski PM, Bach C., Griffin JG and **Adamia S.** MicroRNAs as potential therapeutic agent for AML: Targeting common AML translocation AML1/ETO by the pre-miR-520 and -373. AACR 2015.
16. Brunner AM, Wander SA, Neuberg D, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, Chen YB, Perry AM, Burke M, Silver R, **Adamia S**, Yen K, Yang H, Straley K, Agresta S, Borger DR, Iafrate AJ, Stone RM, Fathi AT. Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations. Blood. 2014;120; Abstract 1045.
17. **Adamia S**, Toniolo P, Fathi AT, Galinsky I, Liu S, Yen K, Kim H, Zhu D, Kim S, Wadleigh M, Steensma DP, Dagogo-Jack I, DeAngelo DJ, Griffin JD, and Stone RM. IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels. Blood. 2014;120; Abstract 1060.
18. **Adamia S**, Bach C, Haibe-Kains B, Pilarski PM, Avet-Loiseau H, Galinsky I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Stone RM, Tenen DG and Griffin JD. Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) could be induced by the modulate expression of splicing factors. Cold Spring Harbor Laboratory conferences, Eukariotic mRNA processing, Long Island, NY, 2013.
19. Jakubikova J, Groen RWJ, **Adamia S**, Hideshima T, Cholutjova D, Laubach JP, Munshi NC, Richardson PG, and Anderson KC. Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. Blood. 2012;120; Abstract 1812

Manuscripts in preparation or in revision:

1. **Adamia S***, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso M, Abiatari I, Letai A, Dorfman D Hideshima T, and Anderson KC*. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia, 2021 (resubmission with minor revisions)
2. Ogiya D, Chyra Z, Verselis SJ, Abiatari I., Hideshima T., Anderson KC., and **Adamia S.** Single nucleotide polymorphisms (SNPs) and recurrent somatic mutations contribute unbalanced RHAMM splicing in multiple myeloma (MM) (Prepared for submission)
3. **Adamia S.** Verselis SJ, Hideshima T, Chu M, Steensma DP, DeAngelo DJ, Dorfman DM, Stone RM, Tenen DG, Pilarski LM, Griffin JD and Anderson KC. Cell type specific deregulation of polypyrimidine tract binding proteins (PTBPs) drives aberrant splicing in multiple myeloma (MM) and acute myeloid leukemia (AML). (In preparation)

4. Vokes N, Weisberg EL, Pilarski PM, Bach C., Tenen DG, Stone RM and Griffin JG and **Adamia S**. MicroRNAs as potential therapeutic agent for AML: Targeting common AML translocation AML1/ETO by the pre-miR-520 and -373. (In preparation)
5. **Adamia S**, Weisberg EL, Bhatt S., Galinsky I, Wadleigh M, Steensma DP, Letai A, DeAngelo DJ., Weinstock D, Dorfman D, Stone RH. and Griffin JD. FLT3 splice variant (FLT3Va) as a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). (Prepared for submission)
6. **Adamia S**, Fathi AT, Galinsky I, Liu S, Yen K, Kim H, Zhu D, Kim S, Wadleigh M, Steensma DP, Dagogo-Jack I, Vokes N, DeAngelo DJ, Griffin JD, and Stone RM. IDH1 splicing alterations in patients with AML and their relationship to blood 2HG Levels- new alternative onco-metabolic pathway in AML. (In preparation)